1. |
Fact sheets:hepatitis B. Geneva:World Health Organization, July. 2013.
|
2. |
He XS, Nanda S, Ji X, et al. Differential Transcriptional Responses to Interferon-alpha and Interferon-gamma in Primary Human Hepatocytes. J Interferon Cytokine Res, 2010, 30(5):311-320.
|
3. |
Janssen HL, Zonneveld MV, Senturk, et al. Pegylated inteferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial. Lancet, 2005, 365:123-129.
|
4. |
干扰素治疗慢性乙型肝炎专家讨论组.干扰素治疗慢性乙型肝炎专家建议.中华传染病杂志, 2007, 25(10):577-583.
|
5. |
万谟彬, 翁心华.干扰素治疗慢性乙型肝炎专家建议的若干补充.中华传染病杂志, 2012, 30(12):705-710.
|
6. |
Moher D, Liberati A, Tetzlaf J, et al. Preferred reporting items for systematic reviews and meta analyses:the PRISMA statement. PLoS Med, 2009, 6(7):e1000097.
|
7. |
中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.肝脏, 2005, 10(4):348-357.
|
8. |
Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011. Available at:http://www.cochrane.org/.
|
9. |
Liu CJ, Wang CC, Yang SS, et al. Entecavir plus Peg-Interferon alfa-2a vs. Entecavir alone in the treatment of Hepatitis B e antigen-positive chronic Hepatitis B. J Hepatol, 2013 (58):S308-309.
|
10. |
曾文, 袁静, 刘映霞, 等.聚乙二醇干扰素alpha-2a联合恩替卡韦治疗高病毒载量HBeAg阳性慢性乙型肝炎的临床研究.中华实验和临床病毒学杂志, 2013, 27(2):115-118.
|
11. |
周一鸣, 曹建彪, 郭汉斌, 等.恩替卡韦联合干扰素治疗e抗原阳性慢性乙型肝炎疗效观察.临床内科杂志, 2013, 30(7):470-472.
|
12. |
李晶. α-干扰素联合恩替卡韦治疗慢性乙型肝炎早期疗效.肝脏, 2012, 17(10):714-716.
|
13. |
毛惠国.恩替卡韦和干扰素序贯联合治疗HBeAg阳性慢性乙型肝炎的疗效分析.现代实用医学, 2012, 24(5):550-551.
|
14. |
范红顺, 何国伟, 彭玲.恩替卡韦与干扰素序贯治疗高病毒载量慢性乙型肝炎的临床疗效.药物与临床, 2012, 2(10):75-76.
|
15. |
李勇.干扰素a-2b与恩替卡韦联合治疗慢性乙型肝炎患者疗效观察.中国实用医药, 2011, 6(35):136-138.
|
16. |
杨琴.恩替卡韦治疗慢性乙型肝炎YMDD变异株的临床分析.现代中西医结合杂志, 2011, 20(36):4668-4669.
|
17. |
罗玮敏, 张迎春, 刘中景.恩替卡韦治疗慢性乙型肝炎的早期临床观察.临床肝胆病杂志, 2008, 24:26-28.
|
18. |
Gao AH, Wang XL, Jiang QH, et al. Clinical observation on influence of livweiwuling tablets combined with entecavir on chronic hepatitis B patients with HBeAg positive. Chin J Liver Dis (Electren Vers), 2011, 3(1):35-37.
|
19. |
苏立稳, 赵凯丰, 王国华.恩替卡韦联合复方肝欣合剂治疗失代偿期乙型肝炎肝硬化临床研究.中西医结合肝病杂志, 2013, 23(2):86-87.
|
20. |
Marcllin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peg-interferon alpha-2a. Gastroenterol, 2009, 136(7):2169-2179.
|
21. |
Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peg-interferon alfa-2a (40KD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int, 2008, 2(1):102-110.
|
22. |
陈新月, 柳雅立.干扰素联合核苷(酸)类似物治疗慢性乙型肝炎的评价与探索.中华传染病杂志, 2014, 32(1):55-58.
|
23. |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of chronic hepatitis B. J Hepatol, 2009, 50 (23):227-242.
|
24. |
Sprinzl MF, Kittner JM, Russo C, et al. Add-on interferon a therapy for increases HBV specific T cell responses in patients with chronic hepatitis B under efficient antiviral nucleoside therapy. Hepatol, 2012, 56(4 Suppl):1058A.
|
25. |
邹川, 苏国彬, 卢富华, 等.一例乙肝相关性肾炎伴肾功能衰竭患者的循证治疗.中国循证医学杂志, 2012, 12(3):360-364.
|
26. |
Sun J, Hou J L, Xie Q, et al. Randomised clinical trial:efficacy of peg-interferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. J Hepatol, 2011, 34(4):424-431.
|